Back to Agenda
Session 3: Artificial Intelligence Panel: Regulatory Affairs in the Age of Artificial Intelligence
Session Chair(s)
Jake Doran
Head of Digital
Lykos Therapeutics, United States
Karen McCarthy Schau
Director, Risk-based Study Management
Vertex Pharmaceuticals, United States
Thomas Noto
Senior Director, Regulatory Operations
Lexicon Pharmaceuticals, United States
In this panel discussion, we will explore how the Regulatory function is positioned in the age of Artificial Intelligence and emerging technologies. From exploring whether it is hype or reality, to evaluating potential use cases, to building business cases, and evaluating organizational readiness for a change of this magnitude; this session will bring together industry leaders to share insight into how Artificial Intelligence will impact Regulatory. As more and more use cases are defined and practical implementation is realized, how will we see the application and impact play out over the next few years?
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand various use cases for Artificial Intelligence across Regulatory
- Understand the challenges and obstacles organizations face when embarking on exploratory initiatives, such as AI
- Learn about the impact a regulated environment and health authorities will have on adoption of this technology
Speaker(s)
Panelist
Christopher Mundy, MS
Clarivate Analytics, United States
Global Life Sciences Solutions Lead
Panelist
Sheila Mahoney Jewels, MBA
LifeSciHub , United States
Drug Development Multi-Functionalist
Panelist
Matt Neal, MA
Atara Biotherapuetics, United States
Senior Director, Regulatory Affairs Operations
Panelist
Sylva Jana Krizan, PhD, RAC
Amazon Web Services (AWS), United States
Global Compliance, Healthcare and Life Sciences
Panelist
Robert Connelly, MBA
Incyte, United States
Senior Director, Global Regulatory Operations
Panelist
Steve Gens, MS
Gens & Associates Inc., United States
Managing Partner
Have an account?